Category: Pharmaceutical Industry
-
UPC Court of Appeal makes UK judge feel even better about his decision: Alexion v. Amgen & Samsung Bioepis
Mr Justice Meade of the High Court of Justice for England & Wales would have reached the same decision anyway, but likes the fact that the UPC CoA interpreted the claim language in the same way.
-
Illumina sues Element Biosciences in Delaware over gene sequencing patents
While this is Illumina’s first official suit against Element Biosciences, the latter has already faced challenges over its gene sequencing technology based on prior art from Illumina’s assets.
-
UPC Dusseldorf issues first decision on second medical use, hands win to Amgen in cholesterol patent dispute against Sanofi
The Dusseldorf Local Division has clarified how the UPC deals with second medical use in patent infringement proceedings, including considering the extent or significance of the allegedly infringing use, and whether an entity is “positively” or “negatively” influencing a market by encouraging infringement, or preventing a product from being used for patented use.
-
ToolGen sues Vertex, Lonza, and RoslinCT over CRISPR patents
ToolGen’s suits come in response to patent oppositions filed by the defendants over its first-ever European CRISPR-Cas9 protein delivery method patent.
-
GSK and Pfizer settle global RSV vaccine patent dispute
The companies announced yesterday that their litigation in the U.S., UK and Unified Patent Court has come to an end, although their dispute over COVID-19 vaccine patent infringement is still pending.
-
Unified Patent Court injunction in 10x Genomics v. NanoString could be reinstated as EPO Opposition Division upholds patent in ‘slightly amended form’
Context: The Unified Patent Court (UPC) opened its doors on June 1, 2023, and only a few months later, in September 2023, 10x Genomics won a preliminary injunction against rival NanoString in the Munich Local Division (LD). NanoString nearly went out of business as a result of that loss, but apparently found an acquirer. The…
-
Genevant Sciences and Arbutus Biopharma file mRNA vaccine patent infringement lawsuits against Moderna in UPC, Switzerland, Japan, Canada
The companies are seeking monetary relief and injunctions against Moderna’s Spikevax® and mRESVIA® vaccinations, among others, alleging that the company is infringing their lipid composition patents in 30 different countries.
-
AstraZeneca expands cancer drug patent enforcement campaign in U.S., seeks preliminary injunctions
AstraZeneca has filed four separate complaints against generic drugmakers Cipla, Sandoz, Natco, and Zydus in the United States District Court for the District of New Jersey.
-
Catalyst and Teva Pharmaceuticals settle patent dispute over rare-disease drug, but fight for orphan treatment not over yet
Nasadaq-listed Catalyst sees shares rise by 18% following the settlement, which grants Teva a license from February 2035.
-
UPC’s Court of Appeal throws out Alexion’s appeals against Amgen and Samsung Bioepis over validity doubts, reveals €100M value of each dispute
The UPC’s Court of Appeal rejects Alexion’s appeals of decisions to deny preliminary injunctions against Amgen and Samsung Bioepis, where the value of the dispute was set at €100M for each case.